Biochemical Recurrent Prostate Cancer Clinical Trial
Official title:
Phase II Trial of Isoflavone in Prostate-specific Antigen Recurrent Prostate Cancer After Previous Local Therapy.
Primary Outcome Measures:
Decrease in rate of serum PSA rise
Secondary Outcome Measures:
Adherence to treatment regimens
Quality of life as assessed by FACT-P at baseline and at 12 months of treatment
Modulation of serum testosterone,isoflavone metabolites, and cholesterol
Estimated Enrollment: 27 Study Start Date: November 2003 Estimated Primary Completion Date:
February 2007 (Final data collection date for primary outcome measure)
- Pretreatment evaluation included a complete medical history, physical examination
(including digital rectal examination), serum PSA, free/total testosterone, lipids,
serum isoflavone levels (genistein, daidzein, and equol), and assessment of quality of
life (Functional Assessment of Cancer Treatment-Prostate, FACT-P questionnaire).
- Whole blood will be obtained prior to initiation of the study to assess for DNA
polymorphism.
- Follow-up serum PSA levels to assess efficacy were obtained at 3, 6, 9, and 12 months
after initiation of treatment.
- Medical history, physical examination, serum testosterone, lipids, isoflavone, and
quality of life were assessed at 6 and 12 months after initiation of treatment.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04206319 -
Radium-223 in Biochemically Recurrent Prostate Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04876755 -
MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer
|
Phase 2 |